Compare · MDGL vs NVS
MDGL vs NVS
Side-by-side comparison of Madrigal Pharmaceuticals Inc. (MDGL) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGL and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 23.0x MDGL ($12.76B).
- Over the past year, MDGL is up 65.7% and NVS is up 34.6% - MDGL leads by 31.1 points.
- MDGL has been more active in the news (5 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 22 for MDGL).
- Company
- Madrigal Pharmaceuticals Inc.
- Novartis AG
- Price
- $553.33+1.41%
- $153.72+0.64%
- Market cap
- $12.76B
- $293.40B
- 1M return
- +10.36%
- +1.89%
- 1Y return
- +65.69%
- +34.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 5
- 1
- Recent ratings
- 22
- 25
Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest MDGL
- Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
- Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Director Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)
- Director Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)
- Director Fouse Jacqualyn A was granted 454 shares, increasing direct ownership by 41% to 1,551 units (SEC Form 4)
- Director Daly James M was granted 454 shares, increasing direct ownership by 17% to 3,081 units (SEC Form 4)
- Director Brennan Daniel J. was granted 404 shares, increasing direct ownership by 42% to 1,371 units (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG